1. Home
  2. GNPX vs ICU Comparison

GNPX vs ICU Comparison

Compare GNPX & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • ICU
  • Stock Information
  • Founded
  • GNPX 2009
  • ICU 2018
  • Country
  • GNPX United States
  • ICU United States
  • Employees
  • GNPX N/A
  • ICU N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • ICU Biotechnology: Pharmaceutical Preparations
  • Sector
  • GNPX Health Care
  • ICU Health Care
  • Exchange
  • GNPX Nasdaq
  • ICU Nasdaq
  • Market Cap
  • GNPX 9.1M
  • ICU 9.5M
  • IPO Year
  • GNPX 2018
  • ICU N/A
  • Fundamental
  • Price
  • GNPX $0.23
  • ICU $0.66
  • Analyst Decision
  • GNPX
  • ICU
  • Analyst Count
  • GNPX 0
  • ICU 0
  • Target Price
  • GNPX N/A
  • ICU N/A
  • AVG Volume (30 Days)
  • GNPX 1.1M
  • ICU 5.7M
  • Earning Date
  • GNPX 08-12-2025
  • ICU 08-12-2025
  • Dividend Yield
  • GNPX N/A
  • ICU N/A
  • EPS Growth
  • GNPX N/A
  • ICU N/A
  • EPS
  • GNPX N/A
  • ICU N/A
  • Revenue
  • GNPX N/A
  • ICU $428,000.00
  • Revenue This Year
  • GNPX N/A
  • ICU $754.07
  • Revenue Next Year
  • GNPX N/A
  • ICU $100.09
  • P/E Ratio
  • GNPX N/A
  • ICU N/A
  • Revenue Growth
  • GNPX N/A
  • ICU N/A
  • 52 Week Low
  • GNPX $0.20
  • ICU $0.31
  • 52 Week High
  • GNPX $3.97
  • ICU $9.09
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 39.16
  • ICU 45.72
  • Support Level
  • GNPX $0.25
  • ICU $0.53
  • Resistance Level
  • GNPX $0.29
  • ICU $0.94
  • Average True Range (ATR)
  • GNPX 0.02
  • ICU 0.10
  • MACD
  • GNPX -0.01
  • ICU 0.01
  • Stochastic Oscillator
  • GNPX 12.22
  • ICU 30.91

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About ICU SeaStar Medical Holding Corporation

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: